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Abstract
Head and neck squamous cell cancers are among the most aggressive. Their incidence and mortality rates are
relatively lower in Middle Africa than worldwide, but in Gabon, these rates tend to be 2–3 fold higher than in
neighboring countries. The main risk factors are alcohol and tobacco consumption. However, in the last decades,
there was cumulated evidence that human papillomaviruses were a significant risk factor, particularly for
oropharyngeal squamous cell cancer. In Gabon, as elsewhere in Africa, assessment of these 3 risk factors need to be
improved to determine their respective role in the development of head and neck squamous cell cancers. The
potential differences in alcohol/tobacco consumption habits as well as in infectious ecology between developing
and developed countries can make it difficult to transpose current data on this issue. Determining the respective
role of alcohol/tobacco consumption and human papillomaviruses in the development of head and neck
squamous cell cancers is crucial for the management of these cancers that could become a serious public health
issue in Gabon. Human papillomaviruses are not only a risk factor but also a biomarker with promising clinical
potential for the follow-up of head and neck squamous cell cancers potentially able to select an adequate
treatment. Then, assessing the epidemiological impact of human papillomaviruses in Gabon and in all of Africa
would prove useful for the clinical follow-up of head and neck squamous cell cancers, and would also provide
essential data to plan a global prevention strategy against head and neck squamous cell cancers due to human
papillomaviruses.
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Background
Head and neck (excluding nasopharyngeal) cancers,
most frequently squamous cell carcinoma, are among
the most aggressive worldwide with 599,637 new cases
diagnosed and 324,834 associated-deaths in 2012 [1, 2].
We study more specifically oral cavity (OCSCC) and
oropharynx (OPSCC) squamous cell carcinomas, still
grouped despite the important anatomic and histological
distinctions [3]. Their main risk factors, involved in 75–
80 % of cases, are tobacco and alcohol [4, 5]. Human
papillomaviruses (HPV) are also a relevant risk factor for
head and neck squamous cell carcinomas (HNSCC),
mainly OPSCC [6, 7]. The relationship between HNSCC
and HPV has been well demonstrated in the United
States of America (U.S.A.) and in Europe where up to
60 % of OPSCC could be attributed to HPV [8–10]. This
raises the issue of HPV vaccination to prevent HNSCC
as well as HPV-induced cervical cancers.
HNSCC risk factors in Middle Africa
Alcohol and tobacco consumption habits vary according
to regions (Table 1) and make it difficult to extrapolate
their impact on HNSCC from developed to developing
countries. Similarly, differences in the infectious ecology
between developed and developing countries complicate
transposing the documented involvement of HPV in
OPSCC to Africa where the profile of HPV infection is
yet to be determined. Furthermore, the impact of HPV,
as well as of alcohol and tobacco on HNSCC in Africa,
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needs to be more extensively studied before defining the
best prevention strategy for HNSCC.
In Middle Africa, the incidence of HNSCC (100,000 new
cases/year) is lower than the worldwide rate (respectively
4.5 versus 8.0), except in Gabon where reported rates are
2–3 fold higher (9.4) (Fig. 1) [1, 11, 12]. However, it is
doubtful that these numbers perfectly reflect the true
HNSCC rates in Middle Africa and in Gabon. As elsewhere
in Africa, cancer registration is not routinely implemented
yet in the healthcare institutions managing cancers. Attrib-
uting the differences between Gabon and the rest of
Middle Africa to a true susceptibility of the Gabonese
population or simply to a better screening/registering/
follow-up of HNSCC is a real challenge. In any case, the
main issue remains: how to manage HNSCC, which could
become a real public health problem, in Gabon?
Tobacco and alcohol consumption in Gabon
The epidemiology of tobacco and alcohol consumption
in Gabon is still poorly documented and assessing their
impact represents is a real challenge in developing coun-
tries. Tobacco and alcohol prevention programs have in-
duced a significant decrease of HNSCC incidence in
developed countries [10]. Similar programs have not
been implemented yet in Africa where tobacco and alco-
hol abuse are increasing [13, 14].
The total alcohol consumption in the Gabonese adult
population (15+) was 26.50 l per capita of pure alcohol
in 2010 (Table 1) compared to 7.90 l in 2005 [15]. The
trend in Gabon was clearly increasing from 2003 to
2010 unlike in the U.S.A and in France where it
remained stable during the same period (Table 1) [14, 15].
This data, mainly based on import/export economic
values, does not take into account indigenous alcoholic
products commonly used in local habits. The alcohol con-
sumption in Gabon as well as its true impact on HNSCC
could thus be underestimated.
The prevalence of current smokers in Gabon in 2011
was estimated at 15.0 % of men and 2.0 % of women in
a population 15 years of age or more (15+) for a global
rate of 9.0 % in this population. These rates are lower
for daily smokers: global rate of 7.0 % with 12.0 % of
men and 1.0 % of women (Table 1). The estimated
prevalence of current smokers was respectively 18.0 and
22.8 % in developed countries such as the U.S.A and
France in 2013. The rate of smokers was much lower in
Table 1 Alcohol and tobacco consumption in the U.S.A, France, and Gabon [13, 14]






2003 – 2005 2008 – 2010 Change Population Drinkers only Current Daily
United States of America 9.5 9.2 → 13.3 16.9 24.5 18.0 14.3
WHO region of Americas 9.2 8.4 _
France 13.4 12.2 → 12.9 29.4 31 22.8 20.1
WHO European region 11.9 10.9 _
Gabon 8.8 10.9 ↗ 26.5 5.3 12.9 9.0 7.0
WHO African region 6.2 6.0 _
aAlcohol per capita consumption (in liter per capita of pure alcohol) among 15+ population
bConsumed at least 60 g or more of pure alcohol on at least one occasion in the past
c2013 data for U.S.A and France except for Gabon (last update in 2011)
Fig. 1 Estimated age-standardized Incidence (ASIR) and Mortality (ASMR) rates of HNSCC in 2012. Graphic representations and associated numbers
(105 persons per year) of incidence and mortality rates of all HNSCC worldwide and in various regions. Bars for Gabon, country of interest here, are in
red/pink whereas they are black/grey for Europe, Northern America, Middle Africa and worldwide (as World). Dark bars (red for Gabon and black for
other regions) represent the incidence rates and the light ones (pink for Gabon and grey for other regions) represent the mortality rates. (Source: GLO-
BOCAN 2012) [1, 2]
Labouba et al. Infectious Agents and Cancer  (2015) 10:40 Page 2 of 4
Gabon (9.0 %) even though increasing (Table 1) as illus-
trated by 2 studies on Gabonese teenagers [13]. 10.9 %
of the population 14–22 years of age smoked in 2007
[16], compared to 21.5 % in the population 10 – 19 years
of age in 2011 [17].
The increasing consumption of tobacco and alcohol
has become a matter of public health concern in Gabon
and requires to be assessed accurately to better under-
stand its impact on HNSCC in the Gabonese population.
The example of betel in India and HNSCC perfectly
illustrates the importance of local habits. The consump-
tion of betel was documented as a major risk factor for
OCSCC in India where tobacco and alcohol consump-
tion is moderate [18].
HPV and cancers in Gabon: screening and
vaccination?
In Africa, most efforts in the prevention of HPV related
cancer are focused on CC, associated with HPV infec-
tion in 80 % of cases. Cervical cancer (CC) is the most
frequently diagnosed and the main cancer-related cause
of death in the female population in Africa as well as in
Gabon, [4, 11, 12]. Nevertheless, in Gabon, systematic
HPV screening has not been integrated yet in the cer-
vical neoplasia detection process. HPV DNA screening
relies essentially on PCR with specific/degenerated pri-
mer systems or on hybrid capture systems largely used
in developed countries. These systems are still too ex-
pensive to implement systematic HPV DNA screening
in Africa, [19]. However, an immunohistochemical ap-
proach could be an affordable alternative with p16 stain-
ing as marker of active HPV infection. The public health
in Africa and Gabon is currently working on the imple-
mentation of efficient programs of early CC screening
that would group cervix cytology and HPV detection. Fi-
nally, this also should allow for developing prevention
strategies by integrating systematic anti-HPV vaccination
in the young female population. These efforts to prevent
CC raise the issue of other HPV-attributable cancers
such as HNSCC.
OPSCC are the most frequent HPV-attributable
HNSCC [20, 21]. The authors of a recent study on a
West African cohort reported that, in Senegal, the low
prevalence (3.4 %) of HPV in HNSCC lesions in 117 pa-
tients suggested no significant association with HPV in-
fection, independently of upper airways anatomic sites.
However, it is important to underline the small number
of OPSCC included (only 4/117 cases) which could lead
to underestimate the true impact of HPV in HNSCC
[22]. To our knowledge, no team has ever evaluated the
cause/effect link between HPV and HNSCC yet, particu-
larly for OCSCC and OPSCC, in Middle Africa including
in Gabon. Furthermore, the prevalence of HPV in HNSCC
as well as the main HPV types remain undocumented.
Nevertheless, this point is essential to evaluate beforehand
the potential impact of anti-HPV vaccination in prevent-
ing HNSCC. Bi- and tetravalent vaccines currently under
clinical trials have been developed against the main genital
HPV types. A new generation nonavalent vaccine could
enlarge the anti-HPV spectrum, however, it is still neces-
sary to document whether HPV in the upper airways
could be targeted [23]. Furthermore, the HPV status
would have an effective prognostic value on the treatment
response and on the survival of HNSCC patients [24, 25].
Kreimer et al. reported that even the presence of specific
HPV 16/18 antibodies could predict HNSCC develop-
ment, stressing the potential clinical value of HPV status
[26]. Thus, the HPV status appears as a promising tool: i)
to plan an adapted prevention strategy, ii) as a biomarker
for a better follow-up of HNSCC patients, particularly in
non-smokers and non-alcohol consumers [21].
Conclusion
HNSCC is becoming a matter of public health concern in
Gabon. It is necessary to control the main risk factors for
their prevention: tobacco, alcohol and HPV. First, it is
imperative to determine accurately the rate of these risk
factors in Gabon. Therefore, local smoking and drinking
habits should be documented to implement adapted pro-
grams to raise the awareness of the Gabonese population.
Moreover, extending HPV research to the whole Gabonese
population is also essential. Numerous ongoing studies are
focused on the female population to determine the HPV
infection profile in a context of CC. Extending this re-
search to HNSCC would be a valuable move to assess the
HPV relative risk. This would ultimately allow for defining
the global epidemiological impact of HPV to elaborate an
effective vaccine anti-HPV strategy thus preventing the
occurrence of HPV-attributable HSNCC.
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